Endogenous stimulus-responsive nitric oxide releasing bioactive liposome for a multilayered drug-eluting balloon. (19th December 2022)

• Record Type: Journal Article
• Authors: Seo, Hyo Jeong; Rhim, Won-Kyu; Baek, Seung-Woon; Kim, Jun Yong; Kim, Da-Seul; Han, Dong Keun
• Is Part Of: Biomaterials science. Volume 11:Number 3(2023)
• Page Start: 916
• Page End: 930
• Publication Date: 2022-12-19
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/d2bm01673g
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : Drug eluting balloon (DEB) system has been designed to enable synergistic therapeutic effects with nitric oxide while reducing the amount of cytostatic drug (EVL), along with the various advantages expected by using a multilayer coating strategy. Abstract : Drug-eluting balloon (DEB) system has been widely utilized for percutaneous coronary intervention (PCI), treating atherosclerosis to overcome the limitations of cardiovascular stents. With the anti-proliferative drug, everolimus (EVL), nitric oxide (NO) plays a key bioregulator role to facilitate the angiogenesis of endothelial cells (ECs) and inhibit the cell proliferation of smooth muscle cells (SMCs) in the lesions of cardiovascular diseases. Due to the very short lifetime and limited exposure area of NO in the body, the continuous release and efficient delivery of NO must be carefully considered. In this respect, a liposome-containing disulfide bonding group was introduced as a delivery vehicle of EVL and NO with the continuous release of NO via successive reaction cycles with GSH and SNAP in the blood vessel without the need for exogenous stimulations. With a multilayer coating platform consisting of a polyvinylpyrrolidone (PVP)/EVL-laden liposome with NO (EVL-NO-Lipo)/PVP, we precluded the loss of the EVL-encapsulated liposome with NO release during the transition time and maximized the transfer rate from the surface of DEB to the tissues. The sustained release of NO was monitored using a nitric oxide analyzer (NOA), and the synergistic bioactivities of EVL and NO were proved in EC and SMC with angiogenesis and cell proliferation-related assays. From the results of hemocompatibility and ex vivo studies, the feasibility was provided for future in vivo applications of the multilayer-coated DEB system.